- Policy
- Gov't opposes to suspending reimb·ingredient prescribing
- by Lee, Jeong-Hwan Oct 17, 2024 05:52am
- The government has opposed the proposed measure, which aims to minimize the chaos in prescription·dispensing by suspending insurance reimbursement or blocking prescription code of drugs when substitute drugs are available. Suspending reimbursement of drugs covered by insurance is a temporary measure implemented in the case of administr
- Policy
- HIRA President, "Copayment ratio needs to be adjusted
- by Lee, Tak-Sun Oct 17, 2024 05:51am
- HIRA President Jung-Gu Kang said that the copayment ratio should be adjusted for anticancer drugs that lack verification of effectiveness. Kang said during the parliamentary audit by the Health and Welfare Committee, "We must lower the patient access hurdle and increase monitoring." Adding, "Especially because we evaluate high-cost drugs
- Policy
- Alvogen receives approval for its Humira biosimilar in KOR
- by Lee, Hye-Kyung Oct 17, 2024 05:51am
- A fifth Humira biosimilar has been approved in Korea. On the 15th, the Ministry of Food and Drug Safety approved Alvogen Korea's Simlandi pen40mg/0.4mL (adalimumab, recombinant), Simandi Prefilled Syringe Inj 40mg/0.4mL and 80mg/0.8mL.. Simlandi is imported and manufactured on consignment by Alvotech, a subsidiary of Alvogen Korea.
- Opinion
- [Reporter’s View] Deadlines are set for a reason
- by Eo, Yun-Ho Oct 17, 2024 05:51am
- The definition of ‘deadline’ is a time limit set in advance. So what is the right thing to do if the deadline has ended without a conclusion being made? Providing a justifiable explanation is very important in administrative affairs. Explanations are necessary not only in the course of introducing or abolishing a system, but also when e
- Product
- Wegovy's price varies by pharmacy in Korea
- by Jung, Heung-Jun Oct 17, 2024 05:51am
- The price of Wegovy, which has been attracting much attention since its launch in Korea, has been found to vary greatly, ranging from KRW 420,000 to KRW 800,000. Some pharmacists who have not yet decided on the selling price are referring to the prices of in-house prescriptions at hospitals and local pharmacies. The prices of Wegovy at p
- Policy
- ‘Will raise ICER threshold for innovative new drugs’
- by Lee, Jeong-Hwan Oct 16, 2024 05:50am
- The government has reaffirmed its policy to flexibly evaluate the ICER (incremental cost-effectiveness ratio) threshold for drugs that demonstrate innovativeness in order to strengthen patient access to new drugs. The intent is to increase the ICER threshold of new drugs based on previously announced criteria such as substitutability, pro
- Opinion
- [Reporter's view] Expanding NIP to include 9-vHPV
- by Whang, byung-woo Oct 16, 2024 05:50am
- Several treatment-related agenda items were discussed during this year's parliamentary audit of the Ministry of Health and Welfare (MOHW). Various current measures, including improvements to the drug pricing system and blood cancers, have been discussed. One is the necessity of including human immunodeficiency virus (hereafter referred to
- Policy
- Govt ‘is considering measures to overcome Korea Passing’
- by Lee, Jeong-Hwan Oct 16, 2024 05:50am
- The government has responded that it will come up with measures to ensure a stable supply of new drugs, including a dual pricing system, to overcome the so-called ‘Korea passing’ phenomenon, in which domestic and foreign pharmaceutical companies avoid launching their drugs in the domestic market and target overseas markets first, citing ex
- Policy
- Stopping illegal online sales·advertisements of 'Wegovy'
- by Lee, Hye-Kyung Oct 16, 2024 05:50am
- As 'Wegovy,' a dream treatment for obesity, is set to launch in South Korea, the health authority plans to focus on monitoring online illegal sales and fraudulent advertising. It will also implement post-marketing safety management related to side effects and drug abuse. The Ministry of Food and Drug Safety (Minister Oh Yu-kyoung, MFDS) a
- InterView
- "JAK inhibitors bring a paradigm shift to RA treatment"
- by Whang, byung-woo Oct 16, 2024 05:50am
- As patients with autoimmune diseases, including rheumatoid arthritis, have better access to medical care, early diagnosis and treatment have been pointed out as the key. Early diagnosis and treatments previously available in university hospitals are now possible in local clinics. As a result, patient-personalized therapies, even for patients
